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Abstract
 
The mechanisms that determine whether receptor stimulation leads to lymphocyte tolerance
versus activation remain poorly understood. We have used rat insulin promoter (RIP)-gp/P14
double-transgenic mice expressing the lymphocytic choriomeningitis virus (LCMV) glycopro-
tein (gp) on pancreatic 
 
b
 
-islet cells together with T cells expressing an LCMV-gp–specific T
cell receptor to assess the requirements for the induction of autoimmunity. Our studies have
shown that administration of the gp peptide gp33 leads to the activation of P14-transgenic T
cells, as measured by the upregulation of activation markers and the induction of effector cyto-
toxic activity. This treatment also leads to expansion and deletion of P14 T cells. Despite the
induction of cytotoxic T lymphocyte activity, peptide administration is not sufficient to induce
diabetes. However, the administration of gp peptide together with an activating anti-CD40 an-
tibody rapidly induces diabetes. These findings suggest that the induction of tolerance versus
autoimmunity is determined by resting versus activated antigen-presenting cells.
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Introduction
 
Specific T lymphocyte interactions that lead to the induc-
tion of peripheral tolerance versus autoimmunity remain
poorly understood. Models have proposed that costimula-
tion and the presence of second signals are essential for ap-
propriate T cell activation and the induction of immunity
(1, 2). These models suggest that in the absence of costimu-
latory molecular interactions, such as that between B7-1 or
B7-2 on the APC and CD28 receptor on T cells, TCR
stimulation alone leads to tolerance induction. Alternate
models suggest that different subpopulations of APCs de-
fine the outcome of T cell interaction with ligand, where
one population induces tolerance and a second induces T
cell activation (3–5).
Studies have demonstrated, however, that events associ-
ated with mature T cell tolerance induction, particularly
the induction of T cell deletion, share common features
with T cell activation: activation markers are upregulated,
proliferation occurs, and effector functions are induced (6–
8). However, the ultimate outcome of tolerance versus im-
munity or autoimmunity has a dramatically different conse-
quence in vivo.
We have used a transgenic model based on lymphocytic
choriomeningitis virus (LCMV) to examine events that
lead to tolerance versus activation. Rat insulin promoter
(RIP)-glycoprotein (gp)–transgenic mice express LCMV-
gp on pancreatic 
 
b
 
-islet cells under the control of RIP, and
the P14-transgenic mice express a LCMV-gp–specific
TCR (9). In the double-transgenic model (RIP-gp/P14),
LCMV-gp–specific CD8
 
1
 
 T cells are not tolerized but re-
main immunologically unaware of the presence of their an-
tigen and are fully capable of responding to antigen under
the appropriate conditions. Using P14 TCR single-trans-
genic mice, previous studies have shown that peptide ad-
ministration leads to tolerance (10). In addition, previous
studies using RIP-gp single-transgenic mice have shown
that LCMV infection induced diabetes (9). We now com-
bine the models to examine the requirements of how
gp33-induced tolerance can be switched to autoimmunity.
Here, we report that specific TCR–peptide–MHC interac-
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tions between T cells and APCs that normally lead to toler-
ance can be biased toward autoimmunity when the APCs
are activated using an agonistic anti-CD40 antibody in
vivo. Therefore, resting versus activated APCs may be the
key to determining whether peripheral tolerance or immu-
nity is induced.
 
Materials and Methods
 
Mice and Glucose Measurements.
 
The P14, RIP-gp, and RIP-
gp/P14 mouse lines have been previously described (9, 11).
Blood glucose measurements were determined with the Chem-
strip bG test kit (Boehringer Mannheim) and quantitated with
Accu-Chek III (Boehringer Mannheim). Mice with blood glu-
cose levels 
 
.
 
14 mM/liter were considered diabetic.
 
Peptides.
 
Peptides were generated at the Amgen Institute by a
solid-phase method using the Fmoc/tBu-based protocol on an
ABI-431 instrument. The crude product was purified by HPLC
and exceeded 95% purity. Peptide gp33 (KAVYNFATM) defines
the major CTL epitope on the LCMV-gp and is H-2D
 
b
 
 re-
stricted. AV (SGPSNTPPEI) is an H-2D
 
b
 
–restricted adenovirus-
derived peptide.
 
Peptide and Antibody Treatment.
 
Mice received either one or
three intravenous administrations of 5 
 
m
 
g of gp33 in HBSS.
When administered three times, peptide was given every third
day (beginning on day 0). The mice received an additional intra-
venous administration of 100 
 
m
 
g of purified rat anti–mouse
CD40-activating antibody FGK45 (12) or 100 
 
m
 
g of a rat poly-
clonal serum (Bio/Can Scientific) 2 d after each peptide treat-
ment.
 
Flow Cytometry.
 
Single-cell suspensions of spleens were
stained at 4
 
8
 
C in PBS, containing FCS and 0.2% NaN
 
3
 
, with
FITC-conjugated rat anti–mouse CD8 or CD4 and PE-conju-
gated rat anti–mouse V
 
a
 
2 (PharMingen) to assess numbers of
transgenic T cells. Additional staining with biotin-conjugated rat
anti–mouse CD25, CD44, and CD69 (PharMingen) and strepta-
vidin-conjugated red-670 (Life Technologies) was performed to
assess T cell activation. Viable cells (10,000 per sample), gated for
lymphocytes by a combination of forward and side scatter, were
analyzed on a FACScan™ flow cytometer (Becton Dickinson)
using LYSIS II™ software.
 
Cytotoxicity Assay.
 
Ex vivo
 
 
 
cytolytic activities of spleen cells
were determined in a 
 
51
 
Cr-release assay. Single spleen cell suspen-
sions from mice treated 2 d before with gp33 were prepared in
IMDM supplemented with 10% FCS, glutamine, and 2-
 
b
 
-ME.
EL4 (H-2
 
b
 
) target cells were coated with gp33 or AV at a con-
centration of 1 
 
m
 
M and labeled with 
 
51
 
Cr for 1 h. After washing,
10
 
4
 
 target cells were mixed with spleen effector cells at ratios of
90:1, 30:1, 10:1, and 3:1 in 96-well round-bottomed plates. Cells
were incubated for 5 h at 37
 
8
 
C, and 70 
 
m
 
l of supernatant was re-
moved and assayed.
 
Lymphocyte Proliferation Assay.
 
Spleens were collected and
dispersed into single-cell suspensions in IMEM complete media
(10% FCS). Cells were cultured in flat-bottomed 96-well plates
(10
 
5
 
 cells per well) in a total volume of 200 
 
m
 
l in the presence of
10
 
5
 
 cells per well of normal C57BL/6 splenocytes prepulsed with
increasing peptide concentrations. Cells were incubated for 48 h
at 37
 
8
 
C in 5% CO
 
2
 
, at which time 0.5 
 
m
 
Ci of [
 
3
 
H]thymidine was
added. The cells were harvested 18 h later, and cell-associated ra-
dioactivity was determined.
 
IFN-
 
g
 
 Detection.
 
IFN-
 
g
 
 was detected by sandwich ELISA
using the PharMingen cytokine detection protocol. Microtiter
ELISA plates were coated overnight with capture anti–IFN-
 
g
 
 an-
tibody (R4-6A2; PharMingen) at 2 
 
m
 
g/ml at 4
 
8
 
C. Plates were
blocked at room temperature with 3% BSA in PBS. After wash-
ing, serum samples were added neat, in duplicate, for 2 h at room
temperature. The plates were later incubated with 1 
 
m
 
g/ml of bi-
otin-conjugated anti–IFN-
 
g
 
 (XMG1.2; PharMingen) and were
subsequently incubated with horseradish peroxidase–labeled avi-
din (Vector Labs.). The enzyme substrate 
 
O
 
-phenylenediamine
(Sigma-Aldrich) was used for color development. IFN-
 
g
 
 concen-
trations were calculated against murine recombinant IFN-
 
g
 
(PharMingen).
 
Immunohistochemistry.
 
Freshly removed pancreata were im-
mersed in PBS and snap frozen in liquid nitrogen. 5-
 
m
 
m-thick
tissue sections of were cut and fixed in acetone for 10 min. Sec-
tions were then incubated with primary antibody for 30 min at
room temperature. Antibodies used included mAb 169 (anti-
CD8) and mAb M114 (anti–class I MHC). Primary antibodies
were followed by a two-step indirect immunoenzymatic staining
procedure. First, alkaline phosphatase–labeled goat antibodies to
rat Igs were applied for 30 min. Alkaline phosphatase was then
detected by a red color reaction using naphtho-AS-BI phosphate
Figure 1. In vivo peptide treatment of P14-transgenic mice leads to T
cell activation followed by tolerance. P14-transgenic mice were treated
three times, 3 d apart, starting on day 0, with 5 mg of gp33 intravenously.
2 d after the first peptide treatment, spleens were obtained and transgenic
T cells were assessed for cell surface expression of CD69 (a) and for CTL
effector function against gp33-pulsed targets (j) or against control pep-
tide–pulsed targets (h) (b). As negative controls, transgenic T cells from
spleens of untreated P14 mice were assessed for CD69 expression (a) and
for CTL activity against gp33-pulsed targets (d) (b). The number of
splenic transgenic T cells in peptide-treated P14 mice was followed over
time in different cohorts of animals by determining the percentage of
CD81Va21 T cells (c) (n 5 3 mice per time point). In vitro splenic prolif-
erative responses against gp33 and control peptide (AV) were determined
on day 9 for peptide-treated mice (open bars) and nontreated controls
(closed bars) (n 5 2 mice per group; variance ,10%) (d). Data is presented
as mean 6 SEM and represents one of two to three experiments. 
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and New Fuchsin as substrate. Endogenous alkaline phosphatase
was blocked by Levamisol. Sections were counterstained with
Mayer’s hemalum for 2 min. The severity of pancreatic islet infil-
tration by CD8
 
1
 
 cells (insulitis) was measured on a scale of 0–3,
where a severity of 0 
 
5 
 
no insulitis, 1 
 
5 
 
periinsulitis/mild insuli-
tis, 2 
 
5 
 
partial insulitis, and 3 
 
5 
 
complete insulitis.
 
Results and Discussion
 
In the P14 TCR single-transgenic model, tolerance can
be induced with repeated intravenous administration of the
LCMV-gp peptide epitope gp33. Peptide administration
caused the upregulation of T cell activation markers such as
CD69 (Fig. 1 a), CD25, and CD44 (data not shown). In
addition, whereas transgenic T cells from untreated mice
were incapable of lysing peptide pulsed targets ex vivo, in
vivo peptide treatment induced T cell cytolytic activity
(Fig. 1 b). Moreover, peptide administration also induced
the expansion of transgenic T cells, followed by deletion, as
determined by the shift in the number of transgenic T cells
above and below normal baseline numbers (Fig. 1 c). The
remaining P14-transgenic T cells were anergic and no
longer proliferated in response to the gp peptide gp33 (Fig.
1 d; reference 10). Using the RIP-gp/P14 double-trans-
genic model, we examined whether intravenous adminis-
tration of gp33 induced diabetes. Although LCMV-gp–
specific cytotoxic activity was induced, this surprisingly did
not lead to the induction of diabetes (Fig. 2 a).
Previous studies using the RIP-gp model have shown
that diabetes can be induced upon viral infection (9). Viral
infections generally lead to the induction of immunity,
which encompasses the events of APC activation and the
induction of inflammatory responses. Therefore, to exam-
ine the mechanism that leads to autoimmunity rather than
tolerance, we focused on the role of APCs. Recent reports
have demonstrated that the maturation and activation of
APCs can be induced with the ligation of CD40, resulting
in increased capacity to present antigen (13–15) and the in-
duction of CD8
 
1
 
 immunity (16–18). Therefore, RIP-gp/
P14 double-transgenic mice were immunized intrave-
Figure 2. Activation of APCs together with peptide treatment leads to insulitis and diabetes. RIP-gp/P14 double-transgenic mice were treated with
the indicated peptide on day 0 and antibody on days 0 and 2. Blood glucose levels were monitored over time (a) (n . 20). Pancreatic islet infiltration by
CD81 cells was determined on day 3. Three nonserial sections per mouse were assessed for islet number and severity of infiltration, where a severity of 0 5
no insulitis, 1 5 periinsulitis/mild insulitis, 2 5 partial insulitis, and 3 5 complete insulitis (b) (n 5 5 animals per group, 10–20 islets per mouse). Immu-
nohistochemical analysis for CD81 T cells is shown for gp33 and control antibody–treated mice (c) or gp33- and anti-CD40–treated mice (d). 
2024
 
Role of APCs in Tolerance and Autoimmunity
 
nously with gp33 and a rat anti–mouse CD40 activating
antibody FGK45 (12) or rat polyclonal antiserum as an iso-
type-matched control. Studies have shown that administra-
tion of 100 
 
m
 
g of FGK45 in vivo led to the activation of
APCs and the induction of T cell function (reference 17,
18; data not shown). All of the mice that received gp33
plus anti-CD40 antibody were diabetic (Fig. 2 a), in con-
trast to control transgenic mice receiving gp33 and the
control antibody. Thus, the in vivo activation of APCs was
critical for the induction of autoimmunity.
To understand the parameters that lead to the induction
of tolerance versus autoimmunity, we assessed the status of
T cell activity in the spleens of animals given peptide and
anti-CD40 or control antibody. T cell activity was mea-
sured by the upregulation of T cell activation markers, the
induction of effector function, and the infiltration of the
pancreas. The induction of activation markers as well as cy-
totoxic activity was identical in both groups (data not
shown). Treatment with peptide alone induced mild pan-
creatic infiltration (Fig. 2, b and c); however, the severity
of infiltration was insufficient to induce disease. In contrast,
the combination of peptide and anti-CD40 antibody in-
duced severe insulitis (Fig. 2, b and d).
Activation of APCs via CD40 has been shown to lead to
increased production of IL-12, which promotes the release
of IFN-
 
g
 
 (15, 19). Treatment of double-transgenic mice
with peptide and control antibody did not promote the
production of measurable levels of circulating IFN-
 
g
 
.
However, the addition of anti-CD40 to the peptide treat-
ment induced levels of IFN-
 
g
 
 that were detectable in the
serum (Fig. 3 a). Moreover, serum IFN-
 
g
 
 levels correlated
with increased expression of class I in the pancreatic islets
Figure 3. Activation of APCs contributes to autoimmunity by inducing IFN-g production and class I MHC expression. 3 and 5 d after peptide and
antibody treatment, serum samples were collected from animals given gp33 and control antibody or gp33 and anti-CD40 and assessed by ELISA for IFN-g
(a) (dotted line 5 detection limit of the assay; n 5 2 per group; variance ,10%; data represent one of two experiments). Day 3 pancreata of gp33 and
control antibody– (b) or anti-CD40–treated animals (c, d) was assessed by immunohistochemistry for MHC class I (b, c) and CD8 (d) expression (data
representative of four mice per group, two nonserial pancreatic sections per mouse). 
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(Fig. 3, b and c). As lymphocytes normally express MHC
class I at high levels, the degree of class I expression was ex-
amined in islets that had relatively few CD8
 
1
 
 T cell infil-
trates (Fig. 3 d). Therefore, anti-CD40 treatment led to the
activation of APCs in vivo, with an enhanced production
of IFN-
 
g
 
 and enhanced pancreatic islet expression of class I
MHC. This may contribute to enhanced CTL infiltration
of the pancreas and the onset of diabetes.
CD40-mediated APC activation has also been shown to
upregulate the costimulatory molecules B7-1 and B7-2 and
thereby also enhance T cell function (13, 20). To deter-
mine whether the induction of autoimmunity was depen-
dent upon engagement of costimulatory ligands, the P14
and RIP-gp transgenes were bred onto a CD28-deficient
background (21). Immunization of RIP-gp/P14/CD28-
negative mice with gp33 and anti-CD40 resulted in the in-
duction of diabetes with the same incidence and kinetics as
seen in CD28-competent mice (data not shown). There-
fore, CD28/B7 interactions were not crucial for the induc-
tion of CD8-mediated autoimmunity in this model.
To examine whether the activation of APCs influenced
deletion of T cells, P14 TCR–transgenic mice were treated
intravenously with gp33 to induce deletion of the trans-
genic T cells. In addition, the mice received FGK45 or the
isotype-matched control antiserum. As shown in Fig. 4,
treatment with the activating anti-CD40 antibody dramati-
cally inhibited the specific deletion of the CD8
 
1
 
V
 
a
 
2
 
1
 
transgenic T cells. Together, these studies support a model
where T cell activation versus tolerance is governed by
APCs.
In this study, disease was actively induced in RIP-gp/
P14 mice upon the administration of peptide and the acti-
vation of APCs with anti-CD40. However, in other trans-
genic models of autoimmunity, disease has often been
shown to occur spontaneously (22–25). Spontaneous dis-
ease may be due to infection with pathogens present in the
local environment, which could potentially induce the ac-
tivation of APCs. This, together with cross-presentation of
self-antigen, which is normally presented by resting APCs
to induce tolerance, may promote the induction of autoim-
munity (22). Alternatively, the induction of spontaneous
autoimmunity may be due to the transient activation of a
high number of transgenic T cells. Studies have shown that
 
self-antigen that is shed can be cross-presented by bone
marrow–derived APCs to induce peripheral tolerance (7).
In addition, studies have shown that peripheral T cell toler-
ance induction is often preceded by T cell activation (6–8,
10, 26). Thus, if self-antigen is shed in a non-TCR–trans-
genic mouse, the numbers of self-specific T cells being
transiently activated and tolerized are probably not suffi-
cient to cause extensive tissue-specific damage. In a TCR-
transgenic mouse, however, the number of self-specific T
cells is high. If adequate amounts of self-antigen are shed to
induce tolerance, the number of transiently activated T
cells may be sufficient to induce tissue damage, thus pro-
moting disease pathogenesis. However, if little to no self-
antigen is shed, as in the RIP-gp/P14 model (data not
shown), despite the high numbers of antigen-specific T
cells, significant tolerance and activation are not induced
and the T cells remain ignorant of their ligand.
Previous studies have reported that peripheral tolerance
can be inhibited by the presence of bacterial or viral infec-
tions (27, 28). The induction of T cell immunity in the
presence of infectious organisms may be the result of proin-
flammatory agents produced by the organisms, such as LPS.
Early reports demonstrated that bacterial LPS could inter-
fere with the induction of B cell unresponsiveness to 
 
g
 
-glob-
ulin (29). Later studies revealed that LPS could also prevent
the induction of CD4
 
1
 
 T cell tolerance (30, 31). More re-
cent data has shown that LPS can inhibit the induction of
tolerance in adoptively transferred transgenic T cells into
antigen-bearing mice and promote the induction of auto-
immunity (28). In our LCMV double-transgenic model,
the administration of gp33 and LPS can induce diabetes
(data not shown). Such events involve APC activation, as it
has been shown that the injection of LPS leads to dendritic
cell (DC) migration from the marginal zones of the spleen
to the T cell areas of splenic white pulp as well as to DC
maturation and activation (32, 33). Thus, infectious agents
may bias a T cell response from tolerance toward immunity
through the activation of APCs.
Additional reports have demonstrated that activation of
APCs with anti-CD40 can prevent tolerance to tumors
(34, 35) and delay deletion induced by staphylococcal en-
terotoxin B (36). The activation and expansion of DCs
with Flt3 ligand has also been shown to inhibit tolerance
Figure 4. Treatment of P14-transgenic mice
with anti-CD40 inhibits gp33-induced T cell
deletion. P14-transgenic mice were treated
three times, 3 d apart, starting on day 0, with 5
mg of gp33 intravenously. 2 d after each peptide
treatment, mice were given 100 mg of activat-
ing anti-CD40 antibody or a rat polyclonal an-
tiserum intravenously. Splenic numbers of
CD81Va21 transgenic T cells (a) or CD41 T
cells (b) were determined in different cohorts of
mice over time by flow cytometry (n 5 2–3
mice per group per time point). Data is pre-
sented as mean 6 SEM and represents one of
two experiments.2026 Role of APCs in Tolerance and Autoimmunity
induction of adoptively transferred transgenic T cells into
antigen-bearing mice (37). Collectively, studies using in-
fectious agents, LPS, and direct activation of APCs demon-
strate that the activation of APCs can break tolerance.
Our studies have made an important contribution to un-
derstanding the mechanisms that discriminate between the
induction of tolerance versus autoimmunity. This study
suggests that T cell interactions with peptide presented in a
“resting” or naive environment are not sufficient to lead to
autoimmunity. However, activation of APCs via anti-
CD40 leads to enhanced cytokine production, contributing
to a proinflammatory environment and autoimmune diabe-
tes. Although this is an experimental model that examines
the induction of immunity and autoimmunity, these find-
ings suggest that the activation status of APCs plays a signif-
icant role in the mechanisms of clinical autoimmune dis-
ease. It is possible that the genetic predisposition to
autoimmune disease involves factors that enhance or lead
to chronic activation of APCs. Susceptible individuals may
have a defect in peripheral tolerance where self-antigen
shedding occurs in the presence of activated APCs. The ac-
tivation of specific T cells in the presence of chronically ac-
tivated APCs could thus bias T cell interactions from toler-
ance to autoimmunity.
The underlying mechanisms that lead to tolerance versus
immunity have been a central issue for decades. Over the
years, models have identified the importance of the TCR-
specific signal 1 and a costimulatory signal 2 and also have
identified the important role of resident APCs in the “pas-
senger leukocyte” concept (1, 2, 38). More recent models
have focused on the role of the APC in defining the out-
come of tolerance and immunity, which incorporates the
importance of costimulatory molecules that become upregu-
lated after APC activation (5). Our studies provide clear
evidence that resting versus activated APCs are crucial in de-
termining the outcome of T cell–specific interactions. Many
models have provided evidence for physiological events that
can trigger APC maturation and activation, including the
ability of the adaptive immune system to sense “danger” or
to communicate with the innate immune system to discern
infectious from noninfectious self (39, 40). Further studies
are still required to identify the key events that regulate APC
function and the induction of tolerance versus immunity.
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